Gilead Sciences, Inc. $GILD Shares Sold by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,311 shares of the biopharmaceutical company’s stock after selling 6,926 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Gilead Sciences were worth $6,694,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the third quarter worth about $26,000. Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $30,000. MTM Investment Management LLC lifted its position in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares in the last quarter. Kilter Group LLC acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $33,000. Finally, Millstone Evans Group LLC boosted its holdings in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 118 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several recent research reports. Argus increased their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Needham & Company LLC reissued a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Monday, February 23rd. Citigroup restated a “buy” rating on shares of Gilead Sciences in a research note on Friday, March 6th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Finally, Scotiabank boosted their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the chief financial officer directly owned 179,191 shares in the company, valued at $25,844,717.93. This represents a 1.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 309,280 shares of company stock worth $44,068,850 in the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

GILD stock opened at $137.21 on Friday. The company has a 50-day simple moving average of $142.69 and a 200 day simple moving average of $127.77. The company has a market capitalization of $170.34 billion, a P/E ratio of 20.27, a PEG ratio of 1.85 and a beta of 0.37. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.